SOHM, a maker of generic pharmaceutical, nutraceutical, and cosmeceutical products, today unveiled its innovative Salic-2® Gel for acne treatment. This product is also being manufactured as private label by SOHM for Ranbaxy Laboratories Ltd., one of the world's leading pharmaceutical companies and part of Daiichi Sankyo Pharmaceuticals in Japan.
Shailesh Shah, president and CEO of SOHM, explained the unique characteristics of the new product.
"Salic-2® Gel is one of the most innovative products developed by SOHM's dermatology division for the treatment of acne," he stated in the news release. "The product not only ensures that normal acidic mantle is kept consistent but also protects the tender skin from bacteria. We are excited to launch this product following our successful first-quarter launch of our salicylic acid face wash, 'fohm by sohm' at the 2013 Oscars after party, held in Hollywood."
The global skin care industry is forecasted to grow by more than 21 percent from 2010-2015 to generate almost $95 billion and reach a volume in excess of 13 billion units. Sohm is particularly interested in the facial care product segment, which represents more than 64 percent of value of the broader market.
SOHM anticipates that Salic-2® Gel will be a leading player in the skin care industry.
"SOHM team is confident that Salic-2® Gel is going to be a tough industry competitor to similar product categories available in the U.S. market," stated Shah. "The introduction of this second skin care line is consistent with our goal of capturing a significant share of the huge U.S. market through our innovative and expanding cosmeceutical product pipeline."
For more information, visit sohm.com
QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net